INMB Inmune Bio Inc
Price (delayed)
$8.07
Market cap
$185.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.11
Enterprise value
$164.51M
INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The
Highlights
The debt has dropped by 96% year-on-year and by 87% since the previous quarter
INMB's quick ratio is up by 49% YoY and by 19% QoQ
The EPS has declined by 26% year-on-year but it has increased by 3.2% since the previous quarter
The gross profit has shrunk by 91% YoY and by 67% QoQ
The revenue has dropped by 91% year-on-year and by 67% since the previous quarter
Key stats
What are the main financial stats of INMB
Market
Valuations
Earnings
Shares outstanding
22.93M
Market cap
$185.05M
Enterprise value
$164.51M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.57
Price to sales (P/S)
11,496.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11,750.69
Revenue
$14,000
Gross profit
$14,000
Operating income
-$42.64M
Net income
-$42.08M
EBIT
-$42.08M
EBITDA
-$42.08M
Free cash flow
-$33.36M
Per share
Balance sheet
Liquidity
EPS
-$2.11
EPS diluted
-$2.11
Free cash flow per share
-$1.67
Book value per share
$1.45
Revenue per share
$0
TBVPS
$1.16
Total assets
$39.56M
Total liabilities
$7.47M
Debt
$384,000
Equity
$32.1M
Working capital
$15.44M
Debt to equity
0.01
Current ratio
3.14
Quick ratio
2.9
Net debt/EBITDA
0.49
Margins
Efficiency
Dividend
EBITDA margin
-300,585.7%
Gross margin
100%
Net margin
-300,585.7%
Operating margin
-304,535.7%
Return on assets
-87.8%
Return on equity
-124.4%
Return on invested capital
N/A
Return on capital employed
-130.1%
Return on sales
-300,585.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INMB stock price
How has the Inmune Bio stock price performed over time
Intraday
6.32%
1 week
4.4%
1 month
0.5%
1 year
-26.3%
YTD
72.81%
QTD
3.33%
Financial performance
How have Inmune Bio's revenue and profit performed over time
Revenue
$14,000
Gross profit
$14,000
Operating income
-$42.64M
Net income
-$42.08M
Gross margin
100%
Net margin
-300,585.7%
The gross profit has shrunk by 91% YoY and by 67% QoQ
The revenue has dropped by 91% year-on-year and by 67% since the previous quarter
The company's operating income fell by 43% YoY and by 2.6% QoQ
Inmune Bio's net income has decreased by 40% YoY
Growth
What is Inmune Bio's growth rate over time
Valuation
What is Inmune Bio stock price valuation
P/E
N/A
P/B
5.57
P/S
11,496.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11,750.69
The EPS has declined by 26% year-on-year but it has increased by 3.2% since the previous quarter
The P/B is 50% higher than the 5-year quarterly average of 3.5 and 14% higher than the last 4 quarters average of 4.6
INMB's equity is down by 17% since the previous quarter and by 14% year-on-year
The price to sales (P/S) is 138% higher than the 5-year quarterly average of 4551.4
The revenue has dropped by 91% year-on-year and by 67% since the previous quarter
Efficiency
How efficient is Inmune Bio business performance
Inmune Bio's ROE has plunged by 94% YoY and by 6% from the previous quarter
INMB's ROA has shrunk by 93% YoY and by 11% QoQ
Dividends
What is INMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INMB.
Financial health
How did Inmune Bio financials performed over time
The total liabilities has shrunk by 60% YoY and by 47% QoQ
INMB's quick ratio is up by 49% YoY and by 19% QoQ
The debt is 99% smaller than the equity
The debt to equity has dropped by 96% year-on-year and by 88% since the previous quarter
The debt has dropped by 96% year-on-year and by 87% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.